Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Industry Asks for AMED Funding of 50 Billion Yen to Build Big Data Platform
November 6, 2019
- Aso, CEFP Members Talked about Aducanumab at Oct. 28 Meeting, Minutes Reveal
November 6, 2019
- MOF Frets Financial Impact of Pricey Meds for Big Patient Populations, Cites Xolair’s Use in Pollen Allergy
November 5, 2019
- Australia Adds Japan to List of Countries Eligible for Expedited Review of New Drugs
November 5, 2019
- Key Japan Panel OKs Xolair as 1st Antibody Drug for Pollen Allergy
November 1, 2019
- MHLW Orders Label Revision for ADHD Treatment Concerta Based on New Distribution Control Policy
October 31, 2019
- Healthcare Providers Fret over Safety of Alternatives to Ranitidine amid Recalls
October 30, 2019
- PMDA Reviewing ILD Risks for Erleada, Xtandi
October 30, 2019
- MHLW Orders Label Revisions for Takecab to Include Pancytopenia to ADR List
October 30, 2019
- CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary
October 29, 2019
- Insurance Coverage of Cancer Genomic Profiling Tests in Early Stage Is Difficult: MHLW Official
October 29, 2019
- 1,419 ADR Victim Relief Claims Recieved in FY2018: MHLW
October 29, 2019
- 1st Topical JAK Inhibitor in Line for Japan Approval in January
October 28, 2019
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
- Xolair Up for Review for Pollen Allergy, Taltz for Ankylosing Spondylitis on Oct. 31
October 25, 2019
- Kenporen Pushes for No Health Coverage or Higher Copay for OTC-Like Drugs
October 25, 2019
- Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
- Chuikyo Payer Rep Moots Higher Prices for Biosames to Incentivize Biosimilar Development
October 24, 2019
- Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
- Discussions on PMD Law Amendment Bill Start in Extraordinary Diet
October 24, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…